Oral Vancomycin as an Adjuvant Treatment in IBD. Issue 2 (16th July 2019)

• Record Type: Journal Article
• Authors: Ayers, Travis D; Leonard-Puppa, Elaine; Kader, Howard A; Waddell, Jaylyn; Watkins, Runa D; Blanchard, Samra S; Safta, Anca M; Rawal, Nidhi
• Is Part Of: Crohn's & colitis 360. Volume 1:Issue 2(2019)
• Publication Date: 2019-07-16
• Subjects: pediatric IBD -- Crohn's disease -- ulcerative colitis -- vancomycin -- microbiome; Crohn's disease -- Periodicals; Colitis -- Periodicals; 616.344
• DOI: 10.1093/crocol/otz015
• Languages: English
• ISSNs: 2631-827X

Abstract

Abstract: Objective: To study the efficacy of oral vancomycin (POV) treatment in pediatric inflammatory bowel disease (IBD). Methods: We conducted retrospective and prospective chart reviews, identifying patients using the Division's Inflammatory Bowel Disease (IBD) registry, ICD-9 and ICD-10 codes for IBD, and recall of patients receiving POV. Patients aged 2–21 years with active IBD at initiation of POV were included unless they had Clostridium difficile infection or primary sclerosing cholangitis (PSC). Pre- and posttreatment analysis included a Physician Global Assessment (PGA), pediatric ulcerative colitis (UC) activity index (PUCAI), and an abbreviated pediatric Crohn's disease (CD) activity index (PCDAI). The Wilcoxon Signed Ranks test, determined if pre- and post-POV rankings of symptom severity differed. Mann–Whitney U tests assessed improvement in presenting symptoms. Results: Nineteen patients met inclusion criteria (12 CD and 7 UC). POV improved the PGA score in 16 of 19 patients ( P < 0.001). Mean PGA score pretreatment was 3 ± 0.471; posttreatment mean of 1.58 ± 0.769. Abdominal pain ( P < 0.001), diarrhea ( P < 0.002), anemia ( P < 0.002), and blood in stool ( P < 0.001) showed significant improvement. PUCAI and PCDAI scores, pretreatment means of 50 ± 17 and 33 ± 9, respectively, also improved with mean score reduction of 23 in CD and 38 in UC patients after POV initiation ( P -value < 0.0001). This improvement was noted for both IBD subtypes. Conclusions: POV may be an effective adjuvant treatment for pediatric IBD. Its effectiveness is likely due to a combination of its anti-tumor necrosis factor alpha-α activity and its influence on the gut microbiome. Further controlled studies of POV in IBD are warranted to determine the most efficacious use of POV in pediatric IBD. Aim: This study attempts to expand on the current literature to determine efficacy of POV as an adjuvant therapy in treating active IBD in children. Lay Summary: In this review, the authors explored the role of oral vancomycin as an additional treatment in 19 pediatric inflammatory bowel disease (IBD) patients. It was demonstrated to be an improvement in symptoms and in physician's global assessment for both Crohn's and ulcerative colitis patients.